Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 8Other hematologic neoplasm 7Lymphoid 7Plasma cell 6Gastrointestinal 6Myeloid 5Gynecologic 5CNS 4Thoracic 3Head & Neck 2Genitourinary 2Dermatologic 2Tumor-Agnostic 1

Conditions

Vomiting 1Thyroid Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Aprepitant × Head & Neck × Clear all
NCT06697782 2025-01-22

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 4 Completed
600 enrolled
Head & Neck

Thyroid Neoplasms

NCT03572829 2020-07-15

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

ChineseAMS

Phase 2 Completed
44 enrolled
Head & Neck

Head and Neck Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡